Random non‐fasting C–peptide: bringing robust assessment of endogenous insulin secretion to the clinic
- 21 April 2016
- journal article
- clinical trial
- Published by Wiley in Diabetic Medicine
- Vol. 33 (11) , 1554-1558
Abstract
Background: Measuring endogenous insulin secretion using C–peptide can assist diabetes management, but standard stimulation tests are impractical for clinical use. Random non‐fasting C–peptide assessment would allow testing when a patient is seen in clinic.Methods: We compared C–peptide at 90 min in the mixed meal tolerance test (sCP) with random non‐fasting blood C–peptide (rCP) and random non‐fasting urine C–peptide creatinine ratio (rUCPCR) in 41 participants with insulin‐treated diabetes [median age 72 (interquartile range 68–78); diabetes duration 21 (14–31) years]. We assessed sensitivity and specificity for previously reported optimal mixed meal test thresholds for severe insulin deficiency (sCP < 200 pmol//l) and Type 1 diabetes/inability to withdraw insulin (< 600 pmol//l), and assessed the impact of concurrent glucose.Results: rCP and sCP levels were similar (median 546 and 487 pmol//l, P = 0.92). rCP was highly correlated with sCP, r = 0.91, P < 0.0001, improving to r = 0.96 when excluding samples with concurrent glucose < 8 mmol//l. An rCP cut‐off of 200 pmol//l gave 100% sensitivity and 93% specificity for detecting severe insulin deficiency, with area under the receiver operating characteristic curve of 0.99. rCP < 600 pmol//l gave 87% sensitivity and 83% specificity to detect sCP < 600 pmol//l. Specificity improved to 100% when excluding samples with concurrent glucose < 8 mmol//l. rUCPCR (0.52 nmol/mmol) was also well‐correlated with sCP, r = 0.82, P < 0.0001. A rUCPCR cut‐off of < 0.2 nmol/ mmol gave sensitivity and specificity of 83% and 93% to detect severe insulin deficiency, with area under the receiver operating characteristic curve of 0.98.Conclusions: Random non‐fasting C–peptide measures are strongly correlated with mixed meal C–peptide, and have high sensitivity and specificity for identifying clinically relevant thresholds. These tests allow assessment of C–peptide at the point patients are seen for clinical care.Keywords
Funding Information
- Northcott Devon Medical Foundation
- NIHR Exeter Clinical Research Facility
This publication has 17 references indexed in Scilit:
- The clinical utility of C‐peptide measurement in the care of patients with diabetesDiabetic Medicine, 2013
- Lessons From the Mixed-Meal Tolerance TestDiabetes Care, 2013
- EDTA Improves Stability of Whole Blood C-Peptide and Insulin to Over 24 Hours at Room TemperaturePLOS ONE, 2012
- Systematic Assessment of Etiology in Adults With a Clinical Diagnosis of Young-Onset Type 2 Diabetes Is a Successful Strategy for Identifying Maturity-Onset Diabetes of the YoungDiabetes Care, 2012
- Validation of a single‐sample urinary C‐peptide creatinine ratio as a reproducible alternative to serum C‐peptide in patients with Type 2 diabetesDiabetic Medicine, 2011
- Urine C-Peptide Creatinine Ratio Is a Noninvasive Alternative to the Mixed-Meal Tolerance Test in Children and Adults With Type 1 DiabetesDiabetes Care, 2011
- Urinary C-Peptide Creatinine Ratio Is a Practical Outpatient Tool for Identifying Hepatocyte Nuclear Factor 1-α/Hepatocyte Nuclear Factor 4-α Maturity-Onset Diabetes of the Young From Long-Duration Type 1 DiabetesDiabetes Care, 2011
- Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment of β-Cell Function in Therapeutic Trials in Type 1 DiabetesDiabetes Care, 2008
- Predictability of C‐peptide for autoimmune diabetes in young adult diabetic patientsPractical Diabetes International, 2001
- C-peptide and the classification of diabetes mellitus patients in the Early treatment diabetic retinopathy study report number 6Annals of Epidemiology, 1993